Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#266 of 388

Joseph Pantginis

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2017No new ratings since Jul 2025

Analyst rating accuracy & track record

Joseph Pantginis is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 380 of their stock calls across 49 companies. Their picks beat their sector 32% of the time over the next 12 months, and their price targets were reached 6% of the time within a year.

Win % vs sector
32%
PT Hit % (12mo)
6%
Avg sector-excess
−11.8%
Scored calls
380
Tickers
49
Tier
Established

Track record

Quantellect has scored 380 of Joseph Pantginis's stock calls across 49 companies, dating back to 2017. Their rated stocks beat their own sector 32% of the time over the next 12 months. On a typical call, a Pantginis pick returned −11.8% more than its sector over the following year.

Of the scored calls, 380 were bullish (Buy). Most of their coverage sits in Unknown. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
CAPRCapricor Therapeutics Inc
Buy$24.00Jul 2025+157.8%Hit
GNTAGenenta Science SpA ADR
Buy$25.00Jul 2025−77.1%Miss
GNTAGenenta Science SpA ADR
Buy$25.00Jul 2025−77.1%Miss
TVTXTravere Therapeutics Inc
Buy$30.00Jul 2025+260.3%Hit
PDSBPDS Biotechnology Corp
Buy$13.00Jul 2025−50.6%Miss
EWTXEdgewise Therapeutics Inc
Buy$42.00Jun 2025+199.4%Hit
PHIOPhio Pharmaceuticals Corp
Buy$14.00Jun 2025−74.0%Miss
VKTXViking Therapeutics Inc
Buy$102.00Jun 2025+13.9%Miss
LXRXLexicon Pharmaceuticals Inc
Buy$4.00Jun 2025+131.1%Miss
CAPRCapricor Therapeutics Inc
Buy$77.00Jun 2025+177.6%Miss
KRYSKrystal Biotech Inc
Buy$240.00Jun 2025+127.9%Hit
ATNMActinium Pharmaceuticals Inc
Buy$4.00Jun 2025−60.6%Miss
MBRXMoleculin Biotech Inc
Buy$4.00Jun 2025−71.0%Miss
GALTGalectin Therapeutics Inc
Buy$6.00Jun 2025−30.4%Hit
BLRXBioLineRx Ltd
Buy$26.00Jun 2025−48.5%Miss
ESPREsperion Therapeutics Inc
Buy$16.00Jun 2025+173.6%Miss
CLDXCelldex Therapeutics Inc
Buy$50.00Jun 2025+45.0%Miss
CAPRCapricor Therapeutics Inc
Buy$77.00Jun 2025+101.7%Miss
CLDXCelldex Therapeutics Inc
Buy$50.00Jun 2025+43.7%Miss
PDSBPDS Biotechnology Corp
Buy$13.00Jun 2025−52.1%Miss
GRIGRI Bio Inc.
Buy$10.00Jun 2025−108.7%Miss
MBRXMoleculin Biotech Inc
Buy$4.00Jun 2025−101.4%Miss
PHIOPhio Pharmaceuticals Corp
Buy$14.00Jun 2025−80.1%Miss
ATYRaTyr Pharma, Inc.
Buy$35.00Jun 2025−106.7%Miss
XOMAXOMA Royalty Corporation
Buy$104.00May 2025+47.5%Miss
BLRXBioLineRx Ltd
Buy$26.00May 2025−21.3%Miss
CRISCuris Inc
Buy$17.00May 2025−88.7%Miss
ATYRaTyr Pharma, Inc.
Buy$35.00May 2025−97.5%Miss
ARMPArmata Pharmaceuticals Inc
Buy$9.00May 2025+250.8%Hit
CVKDCadrenal Therapeutics, Inc. Common Stock
Buy$32.00May 2025−79.0%Miss
PHGEBiomx Inc
Buy$15.00May 2025−121.2%Miss
ATNMActinium Pharmaceuticals Inc
Buy$4.00May 2025−41.7%Miss
IOVAIovance Biotherapeutics Inc
Buy$20.00May 2025+84.6%Miss
CLDXCelldex Therapeutics Inc
Buy$50.00May 2025+52.9%Miss
BMEABiomea Fusion Inc
Buy$18.00May 2025−15.2%Miss
CLDXCelldex Therapeutics Inc
Buy$80.00May 2025+72.5%Miss
NVCTNuvectis Pharma Inc
Buy$15.00Apr 2025−19.8%Miss
KURAKura Oncology Inc
Buy$40.00Apr 2025+30.3%Miss
ATNMActinium Pharmaceuticals Inc
Buy$4.00Apr 2025−46.6%Miss
TNYATenaya Therapeutics Inc
Buy$5.00Apr 2025+39.3%Miss
VYNEVyne Therapeutics Inc
Buy$4.50Apr 2025−61.0%Miss
ESPREsperion Therapeutics Inc
Buy$16.00Apr 2025+105.2%Miss
VKTXViking Therapeutics Inc
Buy$102.00Apr 2025+24.7%Miss
CMPXCompass Therapeutics Inc.
Buy$24.00Apr 2025+154.7%Miss
VKTXViking Therapeutics Inc
Buy$102.00Apr 2025+34.2%Miss
GRIGRI Bio Inc.
Buy$10.00Apr 2025−104.5%Miss
CMPXCompass Therapeutics Inc.
Buy$24.00Apr 2025+239.0%Miss
PHGEBiomx Inc
Buy$21.00Apr 2025−105.0%Miss
BMEABiomea Fusion Inc
Buy$40.00Apr 2025−35.2%Miss
PHGEBiomx Inc
Buy$21.00Apr 2025−89.8%Miss
Go to

Joseph Pantginis: analyst track record FAQ

Is Joseph Pantginis a good stock analyst?

Yes, by track record. Joseph Pantginis ranks number 266 of 388 of the analysts Quantellect scores, with a Q Score of 15 out of 100. Past results do not guarantee future ones.

What is Joseph Pantginis's win rate?

Joseph Pantginis's win rate is 32%. Across 380 scored calls, their rated stocks beat their sector 32% of the time over the next 12 months. On a typical call they returned −11.8% more than the sector.

What stocks and sectors does Joseph Pantginis cover?

Joseph Pantginis covers 49 companies, with the most coverage in Unknown. See the ratings table above for every scored call and its outcome.

Are Joseph Pantginis's price targets accurate?

Joseph Pantginis's price targets are reached within 12 months 6% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Joseph Pantginis's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Joseph Pantginis rank among Wall Street analysts?

Joseph Pantginis ranks number 266 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.